Please use this identifier to cite or link to this item:
Title: Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study
Author: Ceccato, Adrian
Russo, A.
Barbeta, Enric
Oscanoa, Patricia
Tiseo, Giusy
Gabarrús, Albert
Di Giannatale, Pierluigi
Nogas, Stefano
Cillóniz, Catia
Menichetti, F.
Ferrer Monreal, Miquel
Niederman, Michael S.
Falcone, Marco
Torres Martí, Antoni
Keywords: Pneumònia adquirida a la comunitat
Assaigs clínics
Community-acquired pneumonia
Adrenocortical hormones
Clinical trials
Issue Date: 16-Dec-2021
Publisher: BioMed Central
Abstract: Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide despite correct antibiotic use. Corticosteroids have long been evaluated as a treatment option, but heterogeneous efects on survival have precluded their widespread implementation. We aimed to evaluate whether corticosteroids might improve clinical outcomes in patients with severe CAP and high infammatory responses. Study design and methods: We analyzed two prospective observational cohorts of patients with CAP in Barcelona and Rome who were admitted to intensive care with a high infammatory response. Propensity score (PS) matching was used to obtain balance among the baseline variables in both groups, and we excluded patients with viral pneumonia or who received hydrocortisone. Results: Of the 610 patients admitted with severe CAP, 198 (32%) received corticosteroids and 387 had major criteria for severe CAP. All patients had a baseline serum C-reactive protein above 15 mg/dL. Patients who received corticosteroids were more commonly male, had more comorbidities (e.g., cancer or chronic obstructive pulmonary disease), and presented with signifcantly higher sequential organ failure assessment scores. Eighty-nine patients met major severity criteria (invasive mechanical ventilation and/or septic shock) and were matched per group. Twenty-eightday mortality was lower among patients receiving corticosteroids (16 patients, 18%) than among those not receiving them (28 patients, 31%; p=0.037). After PS matching, corticosteroid therapy reduced the 28-day mortality risk in patients who met major severity criteria (hazard ratio (HR) 0.53, 95% confdence interval (CI) 0.29-0.98) (p=0.043). In patients who did not meet major severity criteria, no benefts were observed with corticosteroid use (HR 0.88 (95%CI 0.32-2.36). Conclusions: Corticosteroid treatment may be of beneft for patients with CAP who have septic shock and/or a high infammatory response and requirement for invasive mechanical ventilation. Corticosteroids appear to have no impact on mortality when these features are not present.
Note: Reproducció del document publicat a:
It is part of: Critical Care, 2021, vol. 25, num. 1, p. 432-438
Related resource:
ISSN: 1364-8535
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
721205.pdf956.42 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons